BioLineRx secures new patent for motixafortide production By Investing.com - Investing.com Australia
| BLRX Stock | ILS 7.70 0.40 4.94% |
About 62% of BioLine RX's investor base is looking to short. The analysis of current outlook of investing in BioLine RX suggests that many traders are alarmed regarding BioLine RX's prospects. The current market sentiment, together with BioLine RX's historical and current headlines, can help investors time the market. In addition, many technical investors use BioLine RX stock news signals to limit their universe of possible portfolio assets.
BioLine |
BioLineRx secures new patent for motixafortide production By Investing.com Investing.com Australia
Read at news.google.com
 |
BioLine RX Fundamental Analysis
We analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
BioLine RX is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
BioLine RX Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLine RX stock to make a market-neutral strategy. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics with similar companies.
Peers
BioLine RX Related Equities
| TSEM | Tower Semiconductor | 2.20 | ||||
| LUMI | Bank Leumi | 1.15 | ||||
| ESLT | Elbit Systems | 0.87 | ||||
| BEZQ | Bezeq Israeli | 0.19 | ||||
| ELAL | El Al | 0.76 |
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |